- Statement of Changes in Beneficial Ownership (4)
05 11월 2008 - 10:01AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Dickson Brian
|
2. Issuer Name
and
Ticker or Trading Symbol
CRITICAL THERAPEUTICS INC
[
CRTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Medical Officer
|
(Last)
(First)
(Middle)
C/O CORNERSTONE THERAPEUTICS INC., 2000 REGENCY PARKWAY, SUITE 255
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/31/2008
|
(Street)
CARY, NC 27518
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Option to Purchase Common Stock (Right to Buy)
|
$0.43
|
10/31/2008
|
|
A
|
|
65473
|
|
(1)
|
8/1/2015
|
Common Stock
|
65473
|
(2)
|
65473
|
D
|
|
Option to Purchase Common Stock (Right to Buy)
|
$0.43
|
10/31/2008
|
|
A
|
|
35712
|
|
(3)
|
3/16/2017
|
Common Stock
|
35712
|
(4)
|
101185
|
D
|
|
Option to Purchase Common Stock (Right to Buy)
|
$0.43
|
10/31/2008
|
|
A
|
|
77377
|
|
(5)
|
5/9/2015
|
Common Stock
|
77377
|
(6)
|
178562
|
D
|
|
Option to Purchase Common Stock (Right to Buy)
|
$1.77
|
10/31/2008
|
|
A
|
|
178562
|
|
(7)
|
8/1/2015
|
Common Stock
|
178562
|
(8)
|
357124
|
D
|
|
Option to Purchase Common Stock (Right to Buy)
|
$3.90
|
10/31/2008
|
|
A
|
|
23808
|
|
(9)
|
10/31/2018
|
Common Stock
|
23808
|
(10)
|
380932
|
D
|
|
Explanation of Responses:
|
(
1)
|
The vesting schedule for this option award is 25% on February 9, 2007, 25% on February 9, 2008, 25% on February 9, 2009, and 25% on February 9, 2010.
|
(
2)
|
Received in the merger (the "Merger") of Neptune Acquisition Corp., a wholly owned subsidiary of Critical Therapeutics, Inc., into Cornerstone BioPharma Holdings, Inc. ("CBPHI") in exchange for stock options to acquire 275,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
|
(
3)
|
The vesting schedule for this option award is 25% on March 16, 2008, 25% on March 16, 2009, 25% on March 16, 2010, and 25% on March 16, 2011.
|
(
4)
|
Received in the Merger in exchange for stock options to acquire 150,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
|
(
5)
|
The vesting schedule for this option award is 25% on December 1, 2005, 25% on December 1, 2006, 25% on December 1, 2007, and 25% on December 1, 2008.
|
(
6)
|
Received in the Merger in exchange for stock options to acquire 325,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
|
(
7)
|
The vesting schedule for this option award is 25% on August 1, 2006, 25% on August 1, 2007, 25% on August 1, 2008, and 25% on August 1, 2009.
|
(
8)
|
Received in the Merger in exchange for stock options to acquire 750,000 shares of CBPHI common stock for $0.42 per share based on an exchange ratio of 0.2380837.
|
(
9)
|
The vesting schedule for this option award is 25% on March 15, 2009, 25% on March 15, 2010, 25% on March 15, 2011, and 25% on March 15, 2012.
|
(
10)
|
Received in the Merger in exchange for stock options to acquire 100,000 shares of CBPHI common stock for $0.93 per share based on an exchange ratio of 0.2380837.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Dickson Brian
C/O CORNERSTONE THERAPEUTICS INC.
2000 REGENCY PARKWAY, SUITE 255
CARY, NC 27518
|
|
|
Chief Medical Officer
|
|
Signatures
|
/s/ David Price, attorney in fact for Brian Dickson pursuant to a power of attorney
|
|
11/3/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Cornerstone Therapeutics Inc. (MM) (NASDAQ:CRTXD)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Cornerstone Therapeutics Inc. (MM) (NASDAQ:CRTXD)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
Cornerstone Therapeutics Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles